CMC2

Across TCGA pan-cancer cohorts, CMC2 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated CMC2 data layer compared with 24 for mass-spec protein and 1 for mutation status.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher CMC2 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated CMC2 expression acts as an unfavorable survival marker, although some lineages such as UCEC and GBM show a favorable association.

UCEC, CCRCC, and HNSC are the cancer types where CMC2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	DFS	Tertile	III,IV	1.000	0.245	.011	20	view →
CCRCC	DFS	Median	III,IV	0.373	0.752	.004	16	view →
HNSC	OS	Tertile	II,III,IV	0.775	0.951	.003	15	view →
LUAD	DFS	Median	All	0.448	0.794	.003	12	view →
GBM	DFS	Tertile	All	0.850	0.616	.033	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

CMC2–UCEC (DFS)

Open the UCEC breakdown →